Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+324K
-
Total reported value, excl. options
-
$626M
-
Value change
-
+$7.1M
-
Number of buys
-
35
-
Number of sells
-
-36
-
Price
-
$22.35
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q3 2021
108 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q3 2021.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 79.4M outstanding shares and own 35.25% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.23M shares), Redmile Group, LLC (2.69M shares), ALKEON CAPITAL MANAGEMENT LLC (2.48M shares), venBio Partners LLC (2.2M shares), WELLINGTON MANAGEMENT GROUP LLP (1.91M shares), BlackRock Inc. (1.87M shares), HHLR ADVISORS, LTD. (1.54M shares), Yiheng Capital Management, L.P. (1.52M shares), Point72 Asset Management, L.P. (1.4M shares), and STATE STREET CORP (1.15M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.